Bhatraju Elenore P, Kennedy Devin N, Gojic Alexander J, Iles-Shih Matthew, Merrill Joseph O, Samet Jeffrey H, Hallgren Kevin A, Tsui Judith I
Department of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.
Addict Sci Clin Pract. 2025 Jan 29;20(1):6. doi: 10.1186/s13722-025-00538-1.
Initiation of buprenorphine for treatment of opioid use disorder (OUD) in acute care settings improves access and outcomes, however patients who use methamphetamine are less likely to link to ongoing treatment. We describe the intervention and design from a pilot randomized controlled trial of an intervention to increase linkage to and retention in outpatient buprenorphine services for patients with OUD and methamphetamine use who initiate buprenorphine in the hospital.
The study is a two-arm pilot randomized controlled trial (N = 40) comparing the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention to treatment as usual. Development of the MIAPP intervention was guided by the information-motivation-behavioral skills model and combines financial rewards via mobile health-based adherence monitoring with the "human touch" of a patient navigator. Participants receive financial incentives for submitting videos of themselves taking buprenorphine via smartphone. The Patient Navigator reviews videos and provides treatment adherence coaching, care coordination and motivational enhancement. The intervention is introduced prior to hospital discharge and is offered for 30 days. The primary outcome is linkage to outpatient buprenorphine care within 30 days of hospital discharge. Secondary outcomes include retention on buprenorphine 90 days post discharge, hospital readmissions, and past 30-day methamphetamine use.
Interventions are needed to increase linkage and retention to outpatient buprenorphine among hospitalized patients with OUD, especially for people who co-use methamphetamine. We will examine the MIAPP intervention to improve buprenorphine adherence and linkage to outpatient treatment in a pilot randomized controlled trial which will provide valuable insights about research approaches for hospitalized patients with substance use disorder.
NCT06027814. Date of Initial Release: 08/30/2023.
03/21/2024.
在急性护理环境中启动丁丙诺啡治疗阿片类物质使用障碍(OUD)可改善可及性和治疗效果,然而,使用甲基苯丙胺的患者与持续治疗的联系较少。我们描述了一项试点随机对照试验的干预措施和设计,该试验旨在增加在医院开始使用丁丙诺啡的患有OUD且使用甲基苯丙胺的患者与门诊丁丙诺啡服务的联系并提高其留存率。
该研究是一项双臂试点随机对照试验(N = 40),将移动健康激励依从性加患者导航(MIAPP)干预措施与常规治疗进行比较。MIAPP干预措施的开发以信息-动机-行为技能模型为指导,将基于移动健康的依从性监测的经济奖励与患者导航员的“人文关怀”相结合。参与者通过智能手机提交自己服用丁丙诺啡的视频可获得经济奖励。患者导航员查看视频并提供治疗依从性指导、护理协调和动机强化。该干预措施在出院前引入,并提供30天。主要结局是出院后30天内与门诊丁丙诺啡护理的联系。次要结局包括出院后90天内丁丙诺啡的留存率、再次入院情况以及过去30天内甲基苯丙胺的使用情况。
需要采取干预措施来增加住院的OUD患者与门诊丁丙诺啡的联系和留存率,尤其是对于同时使用甲基苯丙胺的患者。我们将在一项试点随机对照试验中研究MIAPP干预措施,以改善丁丙诺啡的依从性和与门诊治疗的联系,这将为患有物质使用障碍的住院患者的研究方法提供有价值的见解。
NCT06027814。首次发布日期:2023年8月30日。
2024年3月21日。